Literature DB >> 29147035

Dendrimers for Ocular Drug Delivery.

Michael G Lancina1, Hu Yang2,3,4.   

Abstract

Existing methods of administering ocular drugs are limited in either their safety or efficiency. Nanomedicine therapies have the potential to address this deficiency by creating vehicles that can control drug biodistribution. Dendrimers are synthetic polymeric nanoparticles with a unique highly organized branching structure. In recent years, promising results using dendrimer vehicles to deliver ocular drugs through different routes of administration have been reported. In this review, we briefly summarize these results with emphasis on the dendrimer modifications used to target different ocular structures.

Entities:  

Keywords:  dendrimer; nanomedicine; ocular drug delivery

Year:  2017        PMID: 29147035      PMCID: PMC5683719          DOI: 10.1139/cjc-2017-0193

Source DB:  PubMed          Journal:  Can J Chem        ISSN: 0008-4042            Impact factor:   1.118


  74 in total

Review 1.  Biopharmaceutical considerations in topical ocular drug delivery.

Authors:  N M Davies
Journal:  Clin Exp Pharmacol Physiol       Date:  2000-07       Impact factor: 2.557

Review 2.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.

Authors:  M R Prausnitz; J S Noonan
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

3.  Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

4.  Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.

Authors:  Hu Yang; Puneet Tyagi; Rajendra S Kadam; Christopher A Holden; Uday B Kompella
Journal:  ACS Nano       Date:  2012-08-21       Impact factor: 15.881

5.  Comparison of the effects between intravitreal and periocular injections of adenoviral vectored pigment epithelium-derived factor on suppressing choroidal neovascularization in rats.

Authors:  Hua Yan; Jing Cui; Ying Wang; Yanping Yu
Journal:  Ophthalmic Res       Date:  2012-12-18       Impact factor: 2.892

6.  Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.

Authors:  Shin J Kang; Chandrasekar Durairaj; Uday B Kompella; Joan M O'Brien; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2009-08

7.  Effect of particle size of polymeric nanospheres on intravitreal kinetics.

Authors:  E Sakurai; H Ozeki; N Kunou; Y Ogura
Journal:  Ophthalmic Res       Date:  2001 Jan-Feb       Impact factor: 2.892

8.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

9.  Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors.

Authors:  Robyn Sayner; Delesha M Carpenter; Susan J Blalock; Alan L Robin; Kelly W Muir; Mary Elizabeth Hartnett; Annette L Giangiacomo; Gail Tudor; Betsy Sleath
Journal:  Clin Ther       Date:  2015-07-09       Impact factor: 3.393

Review 10.  Review of ocular drug delivery.

Authors:  Yasmin Sultana; R Jain; M Aqil; Asgar Ali
Journal:  Curr Drug Deliv       Date:  2006-04       Impact factor: 2.565

View more
  9 in total

1.  DenTimol as A Dendrimeric Timolol Analogue for Glaucoma Therapy: Synthesis and Preliminary Efficacy and Safety Assessment.

Authors:  Michael G Lancina; Juan Wang; Geoffrey S Williamson; Hu Yang
Journal:  Mol Pharm       Date:  2018-05-30       Impact factor: 4.939

2.  Mildly Cross-Linked Dendrimer Hydrogel Prepared via Aza-Michael Addition Reaction for Topical Brimonidine Delivery.

Authors:  Juan Wang; Geoffrey S Williamson; Michael G Lancina Iii; Hu Yang
Journal:  J Biomed Nanotechnol       Date:  2017-12       Impact factor: 4.099

Review 3.  Nanocarriers for ocular drug delivery: current status and translational opportunity.

Authors:  Srividya Gorantla; Vamshi Krishna Rapalli; Tejashree Waghule; Prem Prakash Singh; Sunil Kumar Dubey; Ranendra N Saha; Gautam Singhvi
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

Review 4.  Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery.

Authors:  Rajiv Bajracharya; Jae Geun Song; Seung Yun Back; Hyo-Kyung Han
Journal:  Comput Struct Biotechnol J       Date:  2019-09-11       Impact factor: 7.271

Review 5.  Considerations for Polymers Used in Ocular Drug Delivery.

Authors:  Megan M Allyn; Richard H Luo; Elle B Hellwarth; Katelyn E Swindle-Reilly
Journal:  Front Med (Lausanne)       Date:  2022-01-28

Review 6.  Dendrimer-based drug delivery systems: history, challenges, and latest developments.

Authors:  Juan Wang; Boxuan Li; Li Qiu; Xin Qiao; Hu Yang
Journal:  J Biol Eng       Date:  2022-07-25       Impact factor: 6.248

7.  Fabrication and Characterization of Tedizolid Phosphate Nanocrystals for Topical Ocular Application: Improved Solubilization and In Vitro Drug Release.

Authors:  Mohd Abul Kalam; Muzaffar Iqbal; Abdullah Alshememry; Musaed Alkholief; Aws Alshamsan
Journal:  Pharmaceutics       Date:  2022-06-23       Impact factor: 6.525

8.  Perspectives of Positively Charged Nanocrystals of Tedizolid Phosphate as a Topical Ocular Application in Rabbits.

Authors:  Abdullah Alshememry; Musaed Alkholief; Mohd Abul Kalam; Mohammad Raish; Raisuddin Ali; Sulaiman S Alhudaithi; Muzaffar Iqbal; Aws Alshamsan
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

Review 9.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.